血清FPSA/TPSA及性腺激素测定结合核素骨显像在前列腺癌诊断、复发和转移中的临床价值

Objective To evaluate the clinical value of free prostate antigen (FPSA) , total prostate specific antigen (TPSA) , FPSA / TPSA and serum hormones (PRL, FSH, LH, Prog, T, E2) combined with ECT bone imaging in patients with prostate carcinoma. Methods 44 healthy males, 75 patients of benign prostate disease (including 41 of benign prostatic hyperplasia (BPH) and 25 of HBP with acute urinary retention (BPH + AUR) surgery, 9 of acute prostatitis) , and 48 patients with prostate carcinoma were enrolled in this study. Their Gonadal hormones and TPSA, FPSA, FPSA / TPSA were measured. Results ①The level of TPSA and FPSA in patients with prostate carcinoma or benign prostate disease were significantly higher than in healthy control (t1=11.42, t2=12.01, P<0.01); ②hose in patients with prostate carcinoma were obviously higher than in patients with benign prostate disease (t1=10.69, t2=11.18, P<0.01); ③he ratio of FPSA/TPSA in patients with prostate carcinoma was obviously lower than those with BPH 0,=10.69, t2=11.18, P<0.01), but there were no significant differences between patients with BPH+AUR and acute prostatitis (t1=0.73, t2=0.62, P>0.05); ④he FSH and LH of gonadal hormones in patients with prostate carcinoma were obviously higher than in patients with benign prostate diseases and healthy control.鈶?Except patients having operation total correction, the gonadal hormones and FSH/LH, T in patients with prostate carcinoma having different treatment programs all had variances before and after therapy; ⑤TPSA and FPSA in patients with prostate carcinoma having bone metastasis were much higher than those without bone metastasis (t/TPSA=5.38, t/fpsA=4.26, P<0.01), the ratio of FPSA/TPSA between those two had no significant disparity (t=1.61, P>0.05). Conclusion here was great clinlical value of the determination of TPSA and FPSA in diagnosis of prostate carcinoma, identification of prostate carcinoma and benign prostate disease and in judgment of bone metastasis. The ratio of FPSA /TPSA <0.16 is a proper prediction index for diagnosis of prostate carcinoma, FPSA /TPSA might be <0.16 in healthy ones and patients with acute prostatitis or BPH ; but when FPSA / TPSA <0.16, the risk of prostate cancer would increase; Gonadal hormones is useful biomarkers in diagnosis and treatment in patients with prostate carcinoma.

Evaluation of serum FPSA/TPSA and hormone determination combinded with nuclide bone imaging in diagnosis of prostate carcinoma and its recidivation and metastasis